Key Quantitative Figures
Financial Results for Year Ended 31st March 2026:
- Total Revenue: ₹1,61,388.41 lakhs (FY25: ₹1,39,321.72 lakhs)
- Profit Before Tax: ₹32,569.14 lakhs (FY25: ₹27,755.36 lakhs)
- Net Profit: ₹24,446.00 lakhs (FY25: ₹20,894.62 lakhs)
- Basic & Diluted EPS: ₹223.41 (FY25: ₹190.95)
- Total Comprehensive Income: ₹24,404.52 lakhs (FY25: ₹20,856.61 lakhs)
Quarter Ended 31st March 2026:
- Total Revenue: ₹42,167.02 lakhs
- Profit Before Tax: ₹8,427.80 lakhs
- Net Profit: ₹5,968.60 lakhs
- Basic & Diluted EPS: ₹54.55
Segment Revenue FY26:
- Healthcare: ₹1,47,024.61 lakhs
- Education: ₹11,539.07 lakhs
Balance Sheet Position as of 31st March 2026:
- Total Assets: ₹2,06,608.11 lakhs
- Total Equity: ₹1,31,926.52 lakhs
- Current Assets: ₹42,093.79 lakhs
- Cash & Cash Equivalents: ₹6,372.38 lakhs
Cash Flow FY26:
- Net cash from operating activities: ₹36,183.43 lakhs
- Net cash used in investing activities: ₹(23,018.48) lakhs
- Net cash used in financing activities: ₹(5,836.97) lakhs
Dates of Action
- Board Meeting: 22nd May 2026 (commenced at 4:00 PM, concluded at 6:12 PM)
- Record Date for Dividend: 19th August 2026
- 40th Annual General Meeting: 26th August 2026
- Book Closure: 20th August 2026 to 26th August 2026 (both days inclusive)
- Cut-off date for e-voting/AGM eligibility: 19th August 2026
Parties Involved
- Statutory Auditors: VKS Aiyer & Co., Chartered Accountants (FRN: 0000665)
- Cost Auditor: Mr. V. Sakthivel, Cost Accountant (Membership No. 23292) of M/s RKMS & Associates
- Internal Auditor: Mr. G. Jawaharlal, Chartered Accountant
- Managing Director: Dr. Nalla G Palaniswami (DIN: 00013536)
Dividend Information
- Final dividend recommended: 150% on equity capital (₹15 per share of face value ₹10)
- Dividend subject to shareholder approval at ensuing AGM
- Total dividend payout not quantified in disclosure
Capital Structure Impact
- Equity Share Capital remains unchanged at ₹1,094.23 lakhs
- Dividend recommendation represents return to shareholders without capital structure alteration
Financial Impact Assessment
All financial impacts are quantified and presented in the audited results. No contingent exposures or subject-to-approval outcomes disclosed beyond the dividend recommendation requiring shareholder approval.